Document is current
Any future updates will be listed below
-
Authors
Adashek, Jacob J. https://orcid.org/0000-0003-4272-312X
Kato, Shumei
Sicklick, Jason K. https://orcid.org/0000-0003-4403-0271
Lippman, Scott M.
Kurzrock, Razelle https://orcid.org/0000-0003-4110-1214
-
Funding
Funding for this research was provided by:
U.S. Department of Health ; Human Services | NIH | National Cancer Institute (P30 CA023100)
U.S. Department of Health ; Human Services | NIH | National Cancer Institute (P30 CA023100)
U.S. Department of Health ; Human Services | NIH | National Cancer Institute (P30 CA023100)
U.S. Department of Health ; Human Services | NIH | National Cancer Institute (5U01CA180888-08)
U.S. Department of Health ; Human Services | NIH | National Cancer Institute (5UG1CA233198-05)
- License Information
-
More Information
Article History
First Online: 15 December 2023
Competing interests
: J.J.A. serves on the advisory board of CureMatch Inc and as a consultant for datma. S.K. serves as a consultant for Foundation Medicine. He receives speaker’s fee from Roche and advisory board for Pfizer. He has research funding from ACT Genomics, Sysmex, Konica Minolta and OmniSeq. J.K.S. receives research funding from Amgen Pharmaceuticals and Foundation Medicine, consultant fees from Deciphera, speaker’s fees from Deciphera, Foundation Medicine, La-Hoffman Roche, Merck, MJH Life Sciences, and QED Therapeutics. SLM is the co-founder of io9 and is on Biological Dynamics, Inc. Scientific Advisory Board. R.K. has received research funding from Biological Dynamics, Boehringer, Caris, Datar Genomics, Ingelheim, Debiopharm, Foundation Medicine, Genentech, Grifols, Guardant, Incyte, Konica Minolta, Medimmune, Merck Serono, Omniseq, Pfizer, Sequenom, Takeda and TopAlliance; as well as consultant and/or speaker fees and/or on the advisory board for Actuate Therapeutics, AstraZeneca, Bicara Therapeutics, Biological Dynamics, Caris, Daiichi Sankyo, Inc., EISAI, EOM Pharmaceuticals, Iylon, Merck, NeoGenomics, Neomed, Pfizer, Prosperdtx, Roche, TD2/Volastra, Turning Point Therapeutics and X-Biotech; has an equity interest in CureMatch Inc., CureMetrix and IDbyDNA; serves on the Board of CureMatch and CureMetrix; and is a co-founder of CureMatch.
